TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07342478: ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Sponsor: Newave Pharmaceutical Inc · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 306 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07342478 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07342478 Rescue Dossier →